Compare BDTX & XGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BDTX | XGN |
|---|---|---|
| Founded | 2014 | 2002 |
| Country | United States | United States |
| Employees | N/A | 220 |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Medical Specialities |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 104.0M | 99.5M |
| IPO Year | 2020 | 2014 |
| Metric | BDTX | XGN |
|---|---|---|
| Price | $1.38 | $3.81 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 8 | 7 |
| Target Price | ★ $11.00 | $9.43 |
| AVG Volume (30 Days) | ★ 766.3K | 706.4K |
| Earning Date | 11-10-2026 | 11-10-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 130.71 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $10.77 |
| Revenue Next Year | N/A | $9.52 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.39 | $2.59 |
| 52 Week High | $3.97 | $9.22 |
| Indicator | BDTX | XGN |
|---|---|---|
| Relative Strength Index (RSI) | 34.73 | 28.65 |
| Support Level | N/A | $2.90 |
| Resistance Level | $1.94 | $5.13 |
| Average True Range (ATR) | 0.14 | 0.79 |
| MACD | -0.04 | -0.34 |
| Stochastic Oscillator | 0.84 | 5.64 |
Black Diamond Therapeutics Inc is a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with cancer. The foundation of companies has been built upon a deep understanding of cancer genetics, onco-protein structure and function, and medicinal chemistry. Its clinical-stage program, silevertinib (formerly BDTX-1535), a brain-penetrant, fourth-generation epidermal growth factor receptor (EGFR) MasterKey inhibitor, is currently being studied in a Phase 2 clinical trial in patients with epidermal growth factor receptor mutant (EGFRm) non-small cell lung cancer (NSCLC). The Company manages its operations as a single operating segment and single reportable segment.
Exagen Inc is a medical technology company focused on the design, development and commercialization of diagnostic testing products under its AVISE brand. These products are used for the differential diagnosis, prognosis, and monitoring of rheumatic, autoimmune, and related diseases, including systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA). The company operates in one operating segment. The majority of the company's revenue is derived from sales of its testing products.